2000 Participants Needed

Glaucoma Screening for Glaucoma

(G-SEARCH Trial)

AM
DW
Overseen ByDionna Wittberg, MPH
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: University of California, San Francisco
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

What is the purpose of this trial?

The vast majority of glaucoma cases in the United States go undetected and untreated until the late stages of the disease. Open-angle glaucoma is a progressive condition that is asymptomatic in its early to moderate stages and may be amenable to screening through telemedicine-based approaches. This study is a randomized trial to evaluate whether glaucoma screening with established tests (e.g., optical coherence tomography, fundus photography, and tonometry) is more effective for detecting undiagnosed glaucoma cases compared to education alone or delayed intervention.

Do I need to stop my current medications for this trial?

The trial information does not specify whether you need to stop taking your current medications.

What data supports the effectiveness of the treatment Glaucoma Screening with Optical Coherence Tomography (OCT), Color Fundus Photography, and Tonometry?

Research shows that optical coherence tomography (OCT) is effective in screening for glaucoma, especially in high-risk groups, and can help detect early signs of the disease. Additionally, combining OCT with fundus photography improves diagnostic accuracy, making it a useful tool for glaucoma screening.12345

Is glaucoma screening using OCT, color fundus photography, and tonometry safe for humans?

The research articles focus on the effectiveness and diagnostic capabilities of optical coherence tomography (OCT) for glaucoma screening, but they do not provide specific safety data. Generally, OCT, color fundus photography, and tonometry are non-invasive and widely used in eye exams, suggesting they are considered safe for human use.13678

How is the glaucoma screening treatment with OCT, color fundus photography, and tonometry different from other treatments?

This treatment is unique because it uses a combination of optical coherence tomography (OCT), which provides detailed images of the eye's structures, color fundus photography to capture images of the retina, and tonometry to measure eye pressure, making it a comprehensive approach for early detection and monitoring of glaucoma.135910

Research Team

JD

Jeremy D Keenan, MD, MPH

Principal Investigator

University of California, San Francisco

YO

Yvonne Ou, MD

Principal Investigator

University of California, San Francisco

Eligibility Criteria

This trial is for Californians at risk of glaucoma who haven't been diagnosed yet. It's not clear what specific inclusion or exclusion criteria are, but typically participants would need to meet certain age and health requirements.

Inclusion Criteria

I am Hispanic and 65 years old or older.
Must have been seen at the Federally Qualified Health Center (FQHC) within the past month
I am Black and 50 years old or older.
See 1 more

Exclusion Criteria

Patients without a valid phone number or mailing address
Patients who have had an optometry appointment within the past year

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks
1 visit (in-person or virtual)

Treatment

Participants undergo telemedicine-based glaucoma screening using optical coherence tomography, fundus photography, and tonometry

1-2 weeks
1 visit (in-person or virtual)

Follow-up

Participants are monitored for outcomes such as cataract surgery, eyeglasses purchase, and quality of life over a 12-month period

12 months

Treatment Details

Interventions

  • Glaucoma Screening with Optical Coherence Tomography (OCT), Color Fundus Photography, and Tonometry
Trial Overview The study tests if screening with OCT, color fundus photography, and tonometry can detect glaucoma better than just giving out educational brochures. Participants will be randomly assigned to get screened or receive the brochure.
Participant Groups
3Treatment groups
Experimental Treatment
Active Control
Group I: ScreeningExperimental Treatment2 Interventions
Group II: Delayed EducationActive Control1 Intervention
The same as the Educational Brochure arm, but delivered at the conclusion of the study.
Group III: EducationActive Control1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of California, San Francisco

Lead Sponsor

Trials
2,636
Recruited
19,080,000+

Centers for Disease Control and Prevention

Collaborator

Trials
902
Recruited
25,020,000+

References

Screening for glaucoma in high-risk populations using optical coherence tomography. [2022]
Current applications of machine learning in the screening and diagnosis of glaucoma: a systematic review and Meta-analysis. [2020]
Progression of Early Glaucomatous Damage: Performance of Summary Statistics From Optical Coherence Tomography and Perimetry. [2023]
The Use of Optical Coherence Tomography for Early Glaucoma Screening in a Population of Patients with Diabetes. [2023]
Applicability of automatic spectral domain optical coherence tomography for glaucoma mass screening. [2022]
A comparative effectiveness analysis of visual field outcomes after projected glaucoma screening using SD-OCT in African American communities. [2022]
Diagnostic capability of peripapillary retinal thickness in glaucoma using 3D volume scans. [2022]
5-year disease progression of patients across the glaucoma spectrum assessed by structural and functional tools. [2019]
Evaluation of relationship between retinal nerve fiber layer thickness progression and visual field progression in patients with glaucoma. [2021]
10.United Statespubmed.ncbi.nlm.nih.gov
Comparison of Glaucoma Progression Detection by Optical Coherence Tomography and Visual Field. [2022]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security